Abbott, Genentech Form Cancer Pact | Chemical & Engineering News
Volume 85 Issue 27 | p. 11 | Concentrates
Issue Date: July 2, 2007

Abbott, Genentech Form Cancer Pact

Department: Business

Abbott Laboratories and Genentech have formed a collaboration for the research, development, and commercialization of two of Abbott's investigational cancer compounds, known as ABT-263 and ABT-869. The small-molecule compounds, discovered by Abbott scientists, are being described as targeted therapies that promise unique approaches to treating cancer. ABT-263 is a Bcl-2 family protein antagonist that restores apoptosis, or cell death, in cancer cells. ABT-869 is a kinase inhibitor that stops tumors from growing by preventing the growth of blood vessels that supply them.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment